{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-020175","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.410962+00:00","generated_at":"2026-06-05T15:27:11.036693+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TransMedics Q4 revenue $81.2M (+159% YoY); guides FY2024 $360-370M","bullets":["Q4 2023 revenue $81.2M (+159% YoY); net income $4.0M ($0.12 EPS) vs loss of $6.7M in Q4 2022.","Full-year 2023 revenue $241.6M (+159% YoY); net loss narrowed to $25.0M from $36.2M.","Gross margin declined to 59% (Q4) and 64% (FY) from 66% and 70% respectively.","Cash position $394.8M as of Dec 31, 2023.","FY2024 revenue guidance $360-370M, representing 49%-53% growth over 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-020175","json":"https://secwatch.observer/filing/0000950170-24-020175.json","markdown":"https://secwatch.observer/filing/0000950170-24-020175.md","text":"https://secwatch.observer/filing/0000950170-24-020175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/tmdx-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:27:11.036693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52b948d073e61605b83459e2535ab14e48a1ee0d","claim":"TransMedics Group, Inc. reported the year ended December 31, 2023 results: revenue $241.6 million, net income $(25.0) million.","evidence_excerpt":"December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the full year of 2022 ▪ Generated net income of $4.0 million or $0.12 per share in the fourth quarter of 2023 “2023 was a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$241.6 million"},{"label":"Net income","value":"$(25.0) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"604d3a545f93e554ef5b26dc6907d723fde3f3f1","claim":"TransMedics Group, Inc. reported full-year 2024 results: revenue $360 million to $370 million. Guidance initiated.","evidence_excerpt":"TransMedics expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company’s prior year revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"Revenue","value":"$360 million to $370 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"b8cca752114c27c3376d8e0d46cbb1a5f25060cd","claim":"TransMedics Group, Inc. reported the quarter ended December 31, 2023 results: revenue $81.2 million, net income $4.0 million, EPS $0.12 per share.","evidence_excerpt":"patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$81.2 million"},{"label":"Net income","value":"$4.0 million"},{"label":"EPS","value":"$0.12 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}